RxDoctor Payments Data

Onyechi Megafu, MD

Pain Medicine · Huntington, WVNPI 1043690712

Payments from drug & device makers

What this record shows

25 manufacturers reported payments, led by Abbott at 34.4% of the total. Reporting peaked in 2024 at $13,627 and has fallen 71.2% since, to $3,924 in 2025. Among pain medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,810in general payments, 2019–2025

Across 460 payments — averaging $80.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$13K
  • Medtronic$12K
  • Boston Scientific$3K
  • Saluda Medical Americas, Inc.$3K
  • Nevro Corp.$1K
  • Curonix LLC$969
  • plus $3K from 19 others

What the payments were for

  • Travel & lodging$19,83254%
  • Food & beverage$16,97946%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,810 in reported general payments places this provider in the 95th percentile of 35 pain medicine providers in West Virginia.

See all pain medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$125,600
Medicare patients
320
Services billed
1,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,597$58,195
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,617$42,676
Xtampza ErOxycodone Myristate56$29,669
OxycontinOxycodone Hcl27$16,141
Buprenorphine36$8,631
Morphine Sulfate ErMorphine Sulfate145$5,605
Fentanyl83$4,992
Oxycodone Hcl172$3,774
Gabapentin345$3,348
Pregabalin88$1,797
Acetaminophen-CodeineAcetaminophen With Codeine73$1,575
Morphine Sulfate43$1,385
Tizanidine Hcl102$1,377
Methadone Hcl75$1,190
Lidocaine11$680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$282$29,66956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 pain medicine providers in West Virginia.

Other pain medicine in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →